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Cost-Effectiveness of a Heart Failure
Management Program From the
Societal Perspective?
I read with great interest the study by Capomolla et al. (1), which
was recently published in this Journal. The investigators assessed
the cost-effectiveness of an interdisciplinary heart failure manage-
ment program delivered by day-hospital compared with usual care.
In times of increasing pressures to contain health care resource
consumption, the study by Capomolla and colleagues represents an
important contribution to the literature.
The investigators state that their cost-effectiveness analysis was
conducted from the societal perspective, whereas it actually repre-
sents an analysis from the health care perspective. When defining
the perspective of an economic evaluation, the following key issues
need to be considered in order to be in line with a societal
viewpoint:
The type of costs in economic evaluation. In an analysis from
the societal perspective, all costs are included. In addition to health
care costs, productivity costs should have been assessed (2,3). This
is important if the age of the study population is relatively young.
The average age in the study by Capomolla et al. (1) was 56 years.
The researchers might have therefore missed a significant propor-
tion of the costs from a societal perspective, thereby probably
underestimating the cost-effectiveness of the interdisciplinary heart
failure management program, a program that might help to avert
future production losses in that it enables the sick person to work
again or work until later in his or her life.
Time horizon of the analysis. From an economic perspective,
the appropriate time horizon for a trial would include all of the
time when there is resource use related to heart failure (4). Because
heart failure is a chronic disease, a life-long treatment/
management is necessary. Accordingly, to agree with a societal
perspective, the follow-up period of 12  3 months of the
within-trial evaluation might have been expanded within a mod-
eling framework. In such a simulation study, one would describe
the course of the disease with and without the intervention for a
patient’s lifetime. The simulated societal costs and (untruncated)
life-expectancy resulting from the two strategies would then be
compared in an incremental analysis.
The utility of health states. The utility values were elicited
from patients using the time trade-off technique. In a societal
cost-effectiveness analysis, it is not the patients’ utilities but the
utilities that society attributes to the health states experienced by
the patient that should be included in the study. That is, a random
sample of the general public should have been asked to estimate
utilities from the societal perspective. Alternatively, the EuroQoL
questionnaire (5), a generic measure of quality of life, could have
been administered to the patients in the study. Value sets are
available that can be used to attach societal utility values to the
health states described by the patient in the EuroQoL question-
naire.
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We thank Dr. Sendi for the methodological considerations of our
study.
The type of costs in economic evaluation. In our economic
analysis we considered both direct health costs and indirect costs
(as missing profit). The choice of evaluating the former costs was
a consequence of the management strategy. In the analysis of
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